BRIEF-Pfizer Announces Results From Phase 3 HER2CLIMB-05 Trial Of TUKYSA

Reuters12-10

Dec 10 (Reuters) - Pfizer Inc PFE.N:

PFIZER: ANNOUNCED RESULTS FROM PHASE 3 HER2CLIMB-05 TRIAL OF TUKYSA
PFIZER: TUKYSA, TRASTUZUMAB & PERTUZUMAB REDUCED RISK OF DISEASE PROGRESSION/DEATH BY 36% COMPARED TO TRASTUZUMAB & PERTUZUMAB ALONE IN PHASE 3 STUDY
PFIZER: TUKYSA, TRASTUZUMAB & PERTUZUMAB COMBINATION DEMONSTRATED MANAGEABLE SAFETY PROFILE AS FIRST-LINE MAINTENANCE THERAPY
PFIZER: KEY SECONDARY ENDPOINT OF OVERALL SURVIVAL NOT MATURE AT TIME OF ANALYSIS BUT SHOWED NUMERICAL TREND FOR IMPROVEMENT WITH TUKYSA

Further company coverage: PFE.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590874435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590874435","market":"us","top_or_hot":-1,"title":"BRIEF-Pfizer Announces Results From Phase 3 HER2CLIMB-05 Trial Of TUKYSA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pfizer Announces Results From Phase 3 HER2CLIMB-05 Trial Of TUKYSA</title></head><body><p><span>Dec 10 (Reuters)</span><span> - </span>Pfizer Inc <span>PFE.N</span>:</p><ul><li><p>PFIZER: ANNOUNCED RESULTS FROM PHASE 3 HER2CLIMB-05 TRIAL OF TUKYSA</p></li><li><p>PFIZER: TUKYSA, TRASTUZUMAB &amp; PERTUZUMAB REDUCED RISK OF DISEASE PROGRESSION/DEATH BY 36% COMPARED TO TRASTUZUMAB &amp; PERTUZUMAB ALONE IN PHASE 3 STUDY</p></li><li><p>PFIZER: TUKYSA, TRASTUZUMAB &amp; PERTUZUMAB COMBINATION DEMONSTRATED MANAGEABLE SAFETY PROFILE AS FIRST-LINE MAINTENANCE THERAPY</p></li><li><p>PFIZER: KEY SECONDARY ENDPOINT OF OVERALL SURVIVAL NOT MATURE AT TIME OF ANALYSIS BUT SHOWED NUMERICAL TREND FOR IMPROVEMENT WITH TUKYSA</p></li></ul><p>Further company coverage: <span>PFE.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pfizer Announces Results From Phase 3 HER2CLIMB-05 Trial Of TUKYSA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pfizer Announces Results From Phase 3 HER2CLIMB-05 Trial Of TUKYSA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-10 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pfizer Announces Results From Phase 3 HER2CLIMB-05 Trial Of TUKYSA</title></head><body><p><span>Dec 10 (Reuters)</span><span> - </span>Pfizer Inc <span>PFE.N</span>:</p><ul><li><p>PFIZER: ANNOUNCED RESULTS FROM PHASE 3 HER2CLIMB-05 TRIAL OF TUKYSA</p></li><li><p>PFIZER: TUKYSA, TRASTUZUMAB &amp; PERTUZUMAB REDUCED RISK OF DISEASE PROGRESSION/DEATH BY 36% COMPARED TO TRASTUZUMAB &amp; PERTUZUMAB ALONE IN PHASE 3 STUDY</p></li><li><p>PFIZER: TUKYSA, TRASTUZUMAB &amp; PERTUZUMAB COMBINATION DEMONSTRATED MANAGEABLE SAFETY PROFILE AS FIRST-LINE MAINTENANCE THERAPY</p></li><li><p>PFIZER: KEY SECONDARY ENDPOINT OF OVERALL SURVIVAL NOT MATURE AT TIME OF ANALYSIS BUT SHOWED NUMERICAL TREND FOR IMPROVEMENT WITH TUKYSA</p></li></ul><p>Further company coverage: <span>PFE.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0306807586.USD","symbol_name":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nP8N3W406A:1","article_id":"2590874435","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590874435","pubTimestamp":1765372504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pfizer Announces Results From Phase 3 HER2CLIMB-05 Trial Of TUKYSADec 10  - Pfizer Inc PFE.N:PFIZER: ANNOUNCED RESULTS FROM PHASE 3 HER2CLIMB-05 TRIAL OF TUKYSAPFIZER: TUKYSA, TRASTUZUMAB & PERTUZUMAB REDUCED RISK OF DISEASE PROGRESSION/DEATH BY 36% COMPARED TO TRASTUZUMAB & PERTUZUMAB ALONE IN PHASE 3 STUDYPFIZER: TUKYSA, TRASTUZUMAB & PERTUZUMAB COMBINATION DEMONSTRATED MANAGEABLE SAFETY PROFILE AS FIRST-LINE MAINTENANCE THERAPYPFIZER: KEY SECONDARY ENDPOINT OF OVERALL SURVIVAL NOT MATURE AT TIME OF ANALYSIS BUT SHOWED NUMERICAL TREND FOR IMPROVEMENT WITH TUKYSAFurther company coverage: PFE.N ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4592":"伊斯兰概念","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4007":"制药","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999002232.USD":"Allianz Global High Payout USD","PFE":"辉瑞","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4599":"减肥药","BK4581":"高盛持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)"},"translate_title":"简报-辉瑞公布Tukysa 3期HER2CLIMB-05试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.96},"content_text":"BRIEF-Pfizer Announces Results From Phase 3 HER2CLIMB-05 Trial Of TUKYSADec 10 (Reuters) - Pfizer Inc PFE.N:PFIZER: ANNOUNCED RESULTS FROM PHASE 3 HER2CLIMB-05 TRIAL OF TUKYSAPFIZER: TUKYSA, TRASTUZUMAB & PERTUZUMAB REDUCED RISK OF DISEASE PROGRESSION/DEATH BY 36% COMPARED TO TRASTUZUMAB & PERTUZUMAB ALONE IN PHASE 3 STUDYPFIZER: TUKYSA, TRASTUZUMAB & PERTUZUMAB COMBINATION DEMONSTRATED MANAGEABLE SAFETY PROFILE AS FIRST-LINE MAINTENANCE THERAPYPFIZER: KEY SECONDARY ENDPOINT OF OVERALL SURVIVAL NOT MATURE AT TIME OF ANALYSIS BUT SHOWED NUMERICAL TREND FOR IMPROVEMENT WITH TUKYSAFurther company coverage: PFE.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590874435","isCrawlerRequest":true}